-
-
Overview
-
MK 2206 is an allosteric inhibitor acting on the protein kinase B (AKT) signaling pathway. MK 2206 acts as an inhibitor in a non-ATP competitive way. MK 2206 has been investigated for clinical use against various types of cancer in which drug resistance is encountered.
Please contact us at for specific academic pricing.
-
- Properties
-
Overview